IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the appointment of Gunnar Olsson as CEO has been extended.
IRLAB Extends CEO Appointment – December 27, 2023 Read More »
Después de completar su misión principal que consistió en un viaje de exploración al asteroide Bennu, la sonda espacial OSIRIS-REx va a emprender otro viaje, esta vez al asteroide que, de entre todos los que podrían colisionar contra la Tierra, es el que más …
Everest Medicines announced that its New Drug Application for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration for the treatment of primary immunoglobulin A nephropathy in adult patients.
Innovent Biologics, Inc. and Sanegene Bio USA Inc. announce that they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen for the treatment of hypertension.
Procaps Group, S.A. announced its financial results for the three months ended September 30, 2023 and the nine months ended September 30, 2023.
Procaps Group Reports Third Quarter 2023 Results Read More »
PharmaBlock Sciences, Inc., a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API GMP facility at its Zhejiang manufacturing site.
PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site Read More »
Amgen announced that the U.S. Food and Drug Administration has completed its review of the company’s supplemental New Drug Application seeking full approval of LUMAKRAS®.
Amgen Provides Regulatory Update on Status of LUMAKRAS® (Sotorasib) Read More »
Nectin Therapeutics Ltd. announced that it has progressed its Phase 1 clinical trial of NTX1088 to include a combination therapy arm with the immune-oncology drug KEYTRUDA®, MSD’s anti-PD-1 therapy, and expanded the trial to four additional global sites to include Sheba Medical Center, Hadassah Medical Center, Ochsner Health, and City of Hope along with flagship
Nectin Therapeutics Advances Ongoing Clinical Trial and Expands Sites to Israel Read More »
Brainstorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes.
Madryn Asset Management, LP, a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc., disclosed that the Transaction Committee of the Company’s Board of Directors did not pursue a substantive dialogue with Laboratory Corporation of America Holdings – one of the industry’s most logical strategics, with a $19 billion market capitalization –
